Skip to content
clinicaltrialshub.com
Clinical Trials Hub

Clinical trials, drug development and research news

Drug Approvals

New breast cancer pill held tumours in check nearly twice as long

The FDA has approved Roche's giredestrant with everolimus for ESR1-mutated advanced breast cancer, after the evERA trial showed 10 months before progression against 5.5.

The glass entrance of the Yawkey Center for Cancer Care at Dana-Farber Cancer Institute in Boston, which led the evERA trial of giredestrant.
Photo: Ajay Suresh, via Wikimedia Commons · CC BY 4.0
Contents
  1. What is an ESR1 mutation, and why does it matter here?
  2. What did the evERA trial test?
  3. How big was the benefit?
  4. Putting the numbers into everyday terms
  5. Does it help people live longer?
  6. What side effects should people expect?
  7. What did the researchers and Roche say?
  8. How does giredestrant fit with other oral breast cancer drugs?
  9. What comes next in the US?
  10. Can people in the UK get giredestrant?

People with advanced hormone-sensitive breast cancer that carries an ESR1 mutation went a median of 10 months before their cancer grew when they took giredestrant plus everolimus, compared with 5.5 months on a standard hormone drug plus everolimus. On the strength of that result, from the phase 3 evERA trial, the US Food and Drug Administration approved giredestrant on 16 November 2026.

The drug will be sold by Roche, through its US arm Genentech, as Wilserdly. It is a once-daily 30 mg tablet, and everolimus is also a tablet, so the whole regimen is taken at home. The usual hormone partners at this stage are older drugs such as exemestane tablets or fulvestrant, which is given as an injection into muscle.

The approval covers a specific group. Patients must be adults with oestrogen receptor (ER) positive, HER2-negative breast cancer that has spread or cannot be removed by surgery, with an ESR1 mutation found by an FDA-authorised blood test. Their cancer must have come back during or after hormone therapy given after surgery, or grown on at least one hormone-based treatment for advanced disease.

What is an ESR1 mutation, and why does it matter here?

About 70% of breast cancers are oestrogen receptor positive, according to Dana-Farber Cancer Institute, which led the trial. These cancers use the hormone oestrogen as fuel. Standard treatment for advanced disease is a hormone drug, usually an aromatase inhibitor that lowers oestrogen levels, combined with a CDK4/6 inhibitor such as palbociclib, ribociclib or abemaciclib.

That combination often works for years. When it stops working, one common reason is a change in the ESR1 gene, which makes the oestrogen receptor itself. A mutated receptor can switch on without oestrogen, so starving the cancer of the hormone no longer helps.

The evERA paper in The New England Journal of Medicine says roughly 40% of people whose cancer grows after a CDK4/6 inhibitor and hormone therapy have an acquired ESR1 mutation. These mutations usually appear under the pressure of aromatase inhibitors, so they are rarely found in the original tumour. That is why testing is done on a blood sample at the point of progression, looking for fragments of tumour DNA in the bloodstream.

Giredestrant is a selective oestrogen receptor degrader, or SERD. It sticks to the receptor and tags it for destruction, which works whether or not the receptor is mutated. Fulvestrant, the first SERD, has to be injected into muscle. Giredestrant is one of a newer group of SERDs that can be swallowed.

What did the evERA trial test?

evERA (NCT05306340) enrolled 373 people at 133 sites in 13 countries between August 2022 and October 2024. All had ER-positive, HER2-negative advanced breast cancer that had grown after treatment with a CDK4/6 inhibitor plus hormone therapy. People who had already had chemotherapy for advanced disease, or another oral SERD, were excluded.

Participants were randomly assigned to one of two all-tablet regimens:

  • giredestrant 30 mg once a day plus everolimus 10 mg once a day (183 people)
  • the doctor's choice of a standard hormone drug, mostly exemestane, with fulvestrant or tamoxifen allowed after a protocol change, plus everolimus 10 mg once a day (190 people)

Everolimus blocks a growth signal called mTOR, a second escape route that breast cancers use to resist hormone treatment. Pairing it with exemestane has been a standard option after first-line treatment for years. So the trial asked a clean question: does swapping the old hormone partner for giredestrant help?

The median age was about 60, almost all participants were women, and around 15% had not been through the menopause. Pre-menopausal women and men also received a drug to switch off hormone production from the ovaries or testes.

The trial deliberately recruited extra people with ESR1 mutations. In the end 207 of the 373, or 55%, had one, against the roughly 40% expected in routine practice. The main measure was progression-free survival, the time until scans showed the cancer growing or the patient died. It was tested first in the ESR1 group and then in everyone.

evERA was open-label, meaning patients and doctors knew which treatment they were getting. That can colour how scans are read. A blinded central review of the scans gave similar results to the investigators' own readings, according to the NEJM paper. Our guide to open-label and blinded trials explains why that check is useful.

How big was the benefit?

Group Giredestrant plus everolimus Standard hormone drug plus everolimus Hazard ratio
ESR1 mutation (207 people) 10.0 months 5.5 months 0.38
Everyone randomised (373 people) 8.8 months 5.5 months 0.56
No ESR1 mutation detected (exploratory) 5.7 months 5.5 months 0.84

Median progression-free survival, from the NEJM paper. The figure for people without a detected mutation came from an exploratory analysis and did not reach statistical significance.

In the ESR1 group, the hazard ratio of 0.38 means the risk of the cancer growing or the patient dying at any given point was 62% lower on the giredestrant combination. That is the figure Roche leads with in its announcement, and the one the FDA used.

The bottom row tells you where the benefit came from. In people with no detectable ESR1 mutation, progression-free survival was 5.7 months against 5.5. The NEJM authors say the result in the whole trial "must be interpreted in the context of the trial design that enriched for patients with ESR1-mutated tumors". That is why the FDA limited the approval to the mutation group.

Tumours shrank by at least 30% in 27% of ESR1 patients on giredestrant and 14% on the comparison, the FDA says. Among those whose tumours shrank, the response lasted a median of 14.9 months against 7.3.

Putting the numbers into everyday terms

Hazard ratios are hard to picture, so here is the same result in plainer arithmetic using the trial's own figures.

The middle patient on the giredestrant combination went 10.0 months before progression. The middle patient on the comparison went 5.5 months. The difference is 4.5 months, and 10.0 divided by 5.5 is about 1.8, which is where "nearly twice as long" comes from.

For tumour shrinkage, 27 in every 100 patients responded on giredestrant against 14 in every 100 on the comparison. That is 13 extra responders per 100. Put another way, roughly one extra person saw their tumours shrink for every eight people treated with the giredestrant combination. Medians hide a spread. Some people did much better than 10 months, and some did much worse. Our guide to reading trial results in absolute terms walks through the same kind of sums for risk figures.

Does it help people live longer?

It is too early to say. At the interim analysis, the estimated proportion of ESR1 patients alive at 18 months was 71.5% on the giredestrant combination and 50.9% on the comparison. The hazard ratio for death was 0.62, but its confidence interval ran from 0.38 to 1.02. Because that range crosses 1, the trial cannot yet rule out no survival difference, and the result did not meet the bar the researchers set for statistical significance.

The FDA's summary says overall survival data were immature. Follow-up continues, and the final survival analysis will be the stronger test. Plenty of cancer drugs that delay progression go on to show a survival gain, and some do not.

What side effects should people expect?

Most of the side effects in evERA came from everolimus, which both groups took. Mouth sores (stomatitis) affected 47.3% of people on the giredestrant combination and 48.9% on the comparison, and severe cases were uncommon in both groups. The trial strongly recommended an alcohol-free dexamethasone mouthwash to prevent them, an approach taken from an earlier study called SWISH.

Side effect or event Giredestrant plus everolimus Standard hormone drug plus everolimus
Mouth sores 47.3% 48.9%
Diarrhoea 26.9% 22.6%
Anaemia 23.6% 21.0%
Pneumonitis (lung inflammation) 17.0% 12.4%
Serious adverse events 29.1% 23.1%
Slow heart rate (bradycardia) 3.8% 0.5%
Stopped everolimus because of side effects 17.0% 11.8%
Stopped the hormone drug because of side effects 8.2% 6.5%

Figures from the NEJM paper's safety population of 182 and 186 people.

Five people in each group (2.7%) died of an adverse event. The paper lists one of the five in the giredestrant group, from pneumonia, as treatment-related. All bradycardia episodes were mild and had cleared by the data cut-off. The FDA label still carries warnings for bradycardia and for harm to an unborn baby.

People on the giredestrant combination stayed on treatment longer, which partly explains why some side effects were a little more common. The median time on giredestrant was 7.1 months, against 4.6 months for the standard hormone drug.

What did the researchers and Roche say?

Dr Erica Mayer of Dana-Farber, the trial's principal investigator, said the approval "gives patients an important new therapeutic option which substantially improves disease control while also providing the convenience of an all-oral regimen".

Levi Garraway, Roche's chief medical officer, said in the company's release that the regimen "allows advanced breast cancer patients to take their treatment from home". Roche has set a US list price of $22,500 per month, pharmaphorum reports, roughly in line with other oral SERDs.

How does giredestrant fit with other oral breast cancer drugs?

Wilserdly is the fourth oral SERD the FDA has approved, after Orserdu (elacestrant), Inluriyo (imlunestrant) and Etcamah (camizestrant), according to pharmaphorum. Each was approved for a different situation. Elacestrant and imlunestrant are used after earlier hormone treatment has failed. Camizestrant is used with a CDK4/6 inhibitor earlier in the disease.

Giredestrant is the first to be approved alongside everolimus. The NEJM authors suggest that hitting the oestrogen receptor and the mTOR pathway at the same time is why the progression-free survival curves in evERA separated early, without the quick drop seen when oral SERDs are used alone. That claim comes from cross-trial comparisons, which are weak evidence, because no trial has compared the oral SERDs head to head.

Giredestrant has had a setback too. In March 2026 Roche said the persevERA trial, which tested giredestrant with palbociclib as a first treatment for advanced disease, missed its main goal. The evERA result stands on its own. Still, the persevERA miss shows the drug does not win in every setting. Our explainer on what it means when a clinical trial fails covers how to read results like that.

What comes next in the US?

The approval arrived ahead of schedule. In a June 2026 release, Roche said it expected the FDA's decision on evERA in December 2026.

A second, larger decision is due within days. The FDA is reviewing giredestrant as a treatment after surgery for early ER-positive, HER2-negative breast cancer, with a target date of 30 November 2026. That application rests on the lidERA trial of more than 4,100 people, where giredestrant cut the risk of invasive cancer returning or death by 30% compared with standard hormone therapy. At three years, 92.4% of people on giredestrant were alive and free of invasive disease, against 89.6% on standard treatment, Roche reported in June. If approved, Roche says it would be the first new adjuvant hormone therapy in over 20 years.

The FDA also authorised Foundation Medicine's FoundationOne Liquid CDx blood test to pick out patients with ESR1 mutations for this treatment. Without a positive result on an authorised test, a patient does not fit the label.

For other recent FDA cancer decisions, see our reports on the Talzenna and Xtandi approval in hormone-sensitive prostate cancer and the Pimjetmi approval for tenosynovial giant cell tumour.

Can people in the UK get giredestrant?

Not yet. Giredestrant has no marketing authorisation in the UK or EU, according to a February 2026 NIHR horizon-scanning briefing, and Roche has said only that filings outside the US are under way. A UK licence would need the MHRA, and NHS funding in England would then depend on a NICE appraisal. Our guide to how new medicines get approved by the FDA, MHRA and NICE sets out those steps.

The UK already has one oral SERD for this group. NICE recommended elacestrant, sold in the UK as Korserdu, in guidance published in February 2025 for ESR1-mutated advanced breast cancer that has grown after at least 12 months of hormone therapy plus a CDK4/6 inhibitor. The blood test for ESR1 is on the NHS National Genomic Test Directory, and NHS England confirmed in April 2026 that trusts now buy the blood collection kits locally.

evERA did include UK patients. Nottingham University Hospitals NHS Trust is listed among the authors' institutions in the NEJM paper.

If you or someone close to you has ER-positive advanced breast cancer that has grown on a CDK4/6 inhibitor, these are reasonable questions for the oncology team:

  • Has my blood been tested for an ESR1 mutation since my cancer last grew?
  • Would elacestrant, everolimus or a clinical trial suit me next?
  • Are any oral SERD trials recruiting at this hospital or nearby?

Our guide to finding and joining a clinical trial explains how to search UK and international registers.

This article reports a regulatory decision and trial results for general information. It is not medical advice. Do not start, stop or change any treatment without talking to the specialist who manages your care.

Frequently asked questions

What is Wilserdly (giredestrant)?

Wilserdly is Roche's brand name for giredestrant, a once-daily 30 mg tablet that attaches to the oestrogen receptor in breast cancer cells and causes it to be broken down. It belongs to a class called oral SERDs. The FDA approved it on 16 November 2026 for use with everolimus in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation after earlier hormone treatment.

Who is eligible for giredestrant in the US?

Adults with ER-positive, HER2-negative breast cancer that is advanced or has spread, whose tumour DNA shows an ESR1 mutation on an FDA-authorised test such as FoundationOne Liquid CDx. The cancer must have returned during or after hormone therapy given after surgery, or grown on at least one hormone-based treatment for advanced disease. It is given together with everolimus.

How is the ESR1 mutation found?

Usually with a blood test that picks up fragments of tumour DNA circulating in the bloodstream, sometimes called a liquid biopsy. ESR1 mutations tend to develop during treatment with aromatase inhibitors, so testing is done when the cancer grows, not at diagnosis. In England the test is on the NHS National Genomic Test Directory because it is needed for elacestrant.

Does giredestrant help people live longer?

That is not yet known. At an interim look in evERA, an estimated 71.5% of people with ESR1 mutations were alive at 18 months on the giredestrant combination against 50.9% on the comparison, but the difference did not reach statistical significance and the data are immature. The approval rests on longer time before the cancer grew, 10.0 months against 5.5.

When might giredestrant be available on the NHS?

There is no date. Giredestrant is not licensed in the UK or EU, and Roche has not published a UK filing date. It would first need an MHRA licence, then a NICE appraisal for NHS use in England. Meanwhile NICE already recommends another oral SERD, elacestrant, for some people with ESR1-mutated advanced breast cancer.

Sources

  1. FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. US Food and Drug Administration, 2026-11-16
  2. FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer. Roche, 2026-11-16
  3. Giredestrant plus Everolimus in Advanced Breast Cancer (evERA). The New England Journal of Medicine, 2026-10-01
  4. Giredestrant plus Everolimus in Advanced Breast Cancer, author manuscript. PubMed Central, 2026-10-17
  5. FDA approves new oral treatment for patients with advanced breast cancer. Dana-Farber Cancer Institute, 2026-11-16
  6. evERA Breast Cancer, NCT05306340. ClinicalTrials.gov, 2026
  7. Roche joins the oral SERD club as FDA clears Wilserdly. pharmaphorum, 2026-11-17
  8. FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer. Roche, 2026-06-02
  9. Roche's oral SERD fails in Phase III breast cancer trial. Clinical Trials Arena, 2026-03-09
  10. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036). NICE, 2025-02-05
  11. Implementation of circulating tumour DNA (ctDNA) testing in the NHS. NHS England, 2026-04-07
  12. Giredestrant for breast cancer, health technology briefing. NIHR Innovation Observatory, 2026-02

Medical disclaimer: For information only, not medical advice. Speak to a qualified healthcare professional about your care.

The Briefing

Trial results that matter, every Friday.

One email. The week's readouts, approvals and research, explained without hype.

Related reading